- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 29.04. | FDA hits Newron's phase 3 schizophrenia trial with clinical hold in US after patient death | ||
| 29.04. | AstraZeneca restarts £300M investment in UK, but Merck not budging | ||
| 29.04. | Teva inks $700M Emalex buyout to bag near-approval Tourette drug | ||
| 29.04. | AstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trial | ||
| 29.04. | Which blockbuster is GSK gunning for next? CEO Miels is looking to oncology | ||
| 29.04. | GSK walks away from $100M bet on Mersana's STING ADC, pauses mRNA bird flu shot program | ||
| 28.04. | FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board | ||
| 28.04. | Protagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profits | ||
| 28.04. | AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition | ||
| 28.04. | Incyte's JAK inhibitor scores phase 3 vitiligo wins but can't quite shake off Rinvoq | ||
| 28.04. | Erasca hits 'home run' with cancer data as analyst suggests stock drop prompted by patient death | ||
| 28.04. | Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing | ||
| 28.04. | Boehringer links dual agonist to 16.6% weight loss in phase 3, but leaves key questions unanswered | ||
| 28.04. | Novartis CEO 'continuing to evaluate' in vivo CAR-Ts, but no deals in the works | ||
| 27.04. | Seaport Therapeutics, Hemab chart courses for $180M IPOs to fund depression, clotting candidates | ||
| 27.04. | Compass Therapeutics' stock heads south after cancer bispecific misses on overall survival | ||
| 27.04. | Astellas thins early pipeline, swaps out struggling rare disease gene therapy | ||
| 27.04. | Oruka's psoriasis data hailed as 'outright win over Skyrizi,' spurring big blockbuster forecasts | ||
| 27.04. | Intellia races in vivo CRISPR therapy to FDA after phase 3 data paint 'compelling' picture | ||
| 27.04. | Lilly maintains M&A hot streak with $2.3B deal for next-gen JAK inhibitor biotech Ajax | ||
| 27.04. | British biotech VC funding shows 'signs of recovery,' but IPO rebound yet to materialize | ||
| 24.04. | Compass, Usona score FDA national priority vouchers amid Trump administration's psychedelic push | ||
| 24.04. | After Lilly's $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy? | ||
| 24.04. | Chutes & Ladders-Helus shuffles out CEO after two months, adds experience to science board | ||
| 24.04. | Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.